10:18 EDT Genmab (GMAB) falls 7% to $22.44 after J&J declines option on HexaBody-CD38
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab A/S Discloses Executive Share Transactions
- Genmab Grants Stock Units and Warrants to Employees
- Genmab A/S Updates Articles of Association to Enhance Financial Flexibility
- Genmab A/S Announces Capital Increase Following Employee Warrant Exercise
- Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment